Stavzor FDA Approval History
FDA Approved: Yes (Discontinued) (First approved July 29, 2008)
Brand name: Stavzor
Generic name: valproic acid
Dosage form: Capsules
Company: Bionpharma Inc.
Treatment for: Bipolar Disorder, Seizures, Epilepsy, Migraine Prevention
Marketing Status: Discontinued
Stavzor is delayed-release valproic acid formulated in the EnteriCare enteric soft gelatin capsule delivery system designed to minimize GI adverse events. Stavzor is indicated for the treatment of manic episodes associated with bipolar disorder, adjunctive therapy in multiple seizure types (including epilepsy), and prophylaxis of migraine headaches.
Development Timeline for Stavzor
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.